Recent Updates
Recently added Catalysts
BVS Positive Sentiment Score: 60/100

Bioventus Reschedules Reporting of First Quarter Fiscal Year 2023 Financial Results to After Market Close on May 16, 2023

Key Takeaway: Bioventus Inc. announced the rescheduling of its financial results report for the first quarter of fiscal year 2023 to May 16, 2023, after market close. The company is projecting revenues of approximately $119 million and an Adjusted EBITDA of around $17 million for the quarter ending April 1, 2023. Additionally, Bioventus expects to remain compliant with its financial covenants. A conference call to discuss the results will be held at 5:00 p.m. Eastern Time that day.

Market Sentiment Analysis

POSITIVE FACTORS

  • Bioventus is expected to report a revenue of approximately $119 million for Q1 FY 2023.
  • The company anticipates reporting an Adjusted EBITDA of approximately $17 million.
  • They are expected to remain in compliance with all financial covenants.

Full Press Release Details

DURHAM, N.C., May 15, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will now report financial results for the first quarter of fiscal year 2023 after the market closes on Tuesday, May 16, 2023. The Company’s management will host a conference call at 5:00 p.m. Eastern Time that same day to discuss the results and provide a business update.
At this time, the Company expects to report revenue for the quarter ended April 1, 2023, of approximately $119 million and Adjusted EBITDA of approximately $17 million. The Company expects to be in compliance with all of its financial covenants under its bank agreement as of the end of the quarter.
To participate in the conference call, dial 1-833-636-0497 (domestic) or +1-412-902-4241 (international) and refer to the Bioventus, Inc. Conference Call.
A live webcast of the call and accompanying materials will also be provided on the “Investor Relations” section of the Company's website at https://ir.bioventus.com/. The webcast will be archived at the same site and available for replay until May 15, 2024.
Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for Pain Treatments, Restorative Therapies and Surgical Solutions. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com and follow the Company on LinkedIn and Twitter. Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.
Investor and Media Inquiries:

Frequently Asked Questions

When will Bioventus report its Q1 2023 financial results?

Bioventus will report its Q1 2023 financial results on May 16, 2023.

What is Bioventus' expected revenue for Q1 2023?

The company expects approximately $119 million in revenue for Q1 2023.

What time is the conference call held by Bioventus?

The conference call will take place at 5:00 p.m. Eastern Time on May 16, 2023.

How can I access the conference call webcast?

The webcast will be available in the Investor Relations section of Bioventus' website.

What is Bioventus' mission?

Bioventus aims to help patients resume active lives with their healing products.

Last updated: May 15, 2023